Ketamine-Assisted Therapy: 2 Psychedelics Companies Team Up To Expand Reimbursement And Training

Psychedelic therapy training company Fluence partnered with psychedelic healthcare insurance plans provider Enthea to expand reimbursement for services from Fluence-trained clinicians offering ketamine-assisted therapy.

Under this strategic partnership, Fluence will offer clinicians who meet Enthea's participation requirements a 20% discount on psychedelic therapy integration (PTI) and ketamine-assisted psychotherapy (KAP) certificate programs. This discount has the potential to increase to 30% if the number of annual referrals from Enthea exceeds 100 participants. Enthea will consider Fluence's advanced certificate in ketamine-assisted therapy as a top-tier training option for becoming credentialed as a member of its provider network.

“This partnership with Enthea substantially increases access to reimbursement for services from graduates of our training programs," stated Elizabeth Nielson, PhD, co-founder and chief visionary officer of Fluence. "Patients will know that their provider, when credentialed by Enthea, has been trained to the highest industry standard, and Enthea's client employers can rest assured their employees are getting high-quality care. By combining Enthea’s commitment to expanding access to psychedelic-assisted therapy with our expertise in training mental health professionals, we can work together to address the growing need for qualified practitioners in this field.”

The collaboration between Fluence and Enthea comes as interest in psychedelic-assisted therapy continues and the demand for trained practitioners grows.

"Our mission is to remove the barriers that prevent people from accessing highly effective mental health treatments,” Sherry Rais, CEO of Enthea said in a statement.”By partnering with Fluence, we can help ensure that as more people gain access to ketamine-assisted therapy through their employee benefits, there will be a growing network of qualified practitioners ready to provide safe and effective care.”

See Also: FDA Panel Rejects MDMA Therapy For PTSD, Citing Concerns Over Research Data In Setback For Advocates

Photo: Courtesy of Sonis Photography via Shutterstock